StreetInsider.com News Articles

New to The Street broadcasts show #758 TODAY AT 6:30 PM ET on BLOOMBERG TELEVISION ACROSS THE UNITED STATES, LATIN AMERICA, AND MENA

Sat, 20 Jun 2026 13:30:00 -0400

Featured Interviews Include Aeries Technology (NASDAQ: AERT), Virtuix Holdings (NASDAQ: VTIX), and EmpowerLit; Sponsored Programming Supported by DataVault AI (NASDAQ: DVLT), IGC Pharma (NYSE American: IGC), Medicus Pharma (NASDAQ: MDCX), and NRx Pharmaceuticals (NASDAQ: NRXP)

NEW YORK CITY, NY / ACCESS Newswire / June 20, 2026 / New to The Street, one of the world's most widely distributed business television brands, today announced the broadcast of Show #758 airing at 6:30 PM ET on Bloomberg Television throughout the United States, Latin America, and the Middle East and North Africa (MENA) region.

The nationally

New to The Street broadcasts show #758 TODAY AT 6:30 PM ET on BLOOMBERG TELEVISION ACROSS THE UNITED STATES, LATIN AMERICA, AND MENA

Sat, 20 Jun 2026 13:30:00 -0400

The nationally

New to The Street broadcasts show #758 TODAY AT 6:30 PM ET on BLOOMBERG TELEVISION ACROSS THE UNITED STATES, LATIN AMERICA, AND MENA

Sat, 20 Jun 2026 13:30:00 -0400

The nationally

New to The Street broadcasts show #758 TODAY AT 6:30 PM ET on BLOOMBERG TELEVISION ACROSS THE UNITED STATES, LATIN AMERICA, AND MENA

Sat, 20 Jun 2026 13:30:00 -0400

The nationally

New to The Street broadcasts show #758 TODAY AT 6:30 PM ET on BLOOMBERG TELEVISION ACROSS THE UNITED STATES, LATIN AMERICA, AND MENA

Sat, 20 Jun 2026 13:30:00 -0400

The nationally

New to The Street broadcasts show #758 TODAY AT 6:30 PM ET on BLOOMBERG TELEVISION ACROSS THE UNITED STATES, LATIN AMERICA, AND MENA

Sat, 20 Jun 2026 13:30:00 -0400

The nationally

New to The Street broadcasts show #758 TODAY AT 6:30 PM ET on BLOOMBERG TELEVISION ACROSS THE UNITED STATES, LATIN AMERICA, AND MENA

Sat, 20 Jun 2026 13:30:00 -0400

The nationally

New to The Street broadcasts show #758 TODAY AT 6:30 PM ET on BLOOMBERG TELEVISION ACROSS THE UNITED STATES, LATIN AMERICA, AND MENA

Sat, 20 Jun 2026 13:30:00 -0400

The nationally

New to The Street broadcasts show #758 TODAY AT 6:30 PM ET on BLOOMBERG TELEVISION ACROSS THE UNITED STATES, LATIN AMERICA, AND MENA

Sat, 20 Jun 2026 13:30:00 -0400

The nationally

New to The Street broadcasts show #758 TODAY AT 6:30 PM ET on BLOOMBERG TELEVISION ACROSS THE UNITED STATES, LATIN AMERICA, AND MENA

Sat, 20 Jun 2026 13:30:00 -0400

The nationally

Osmind study finds IV ketamine more effective than nasal esketamine for depression

Fri, 05 Jun 2026 08:52:50 -0400

NRx Pharmaceuticals (NASDAQ: NRXP) announced that Osmind, Inc. presented a study at the American Society of Clinical Psychopharmacology conference comparing IV ketamine and intranasal esketamine treatments for depression.

The retrospective study analyzed electronic health records from 8,224 patients with treatment-resistant depression who received IV ketamine and 1,830 patients treated with intranasal esketamine across 800 community psychiatry clinics. After matching patients on baseline characteristics, researchers created an analysis set of 3,560 people.

Results showed 34% of IV ketamine patients achieved remission compared to 26% for intranasal esketamine patients. Response rates were 63% and 58% respectively. IV ketamine patients demonstrated higher rates of remission

Osmind study finds IV ketamine more effective than nasal esketamine for depression

Fri, 05 Jun 2026 08:52:50 -0400

NRx Pharmaceuticals (Nasdaq:NRXP) notes presentation by Osmind, Inc. of IV Ketamine Efficacy vs. Nasal esketamine Efficacy at American Society of Clinical Psychopharmacology.

Fri, 05 Jun 2026 08:50:00 -0400

Osmind presented a retrospective comparative study of de-identified electronic health record data in a sample of 8,224 patients with treatment resistant depression treated with IV ketamine and 1,830 patients treated with intranasal esketamine from 800 community psychiatry clinics.
IV ketamine patients demonstrated significantly higher rates of remission (OR 1.51; P<.001) from depression and response (OR 1.22; P<.003) compared to patients treated with nasal esketamine.
The primary study limitation is that treatment assignments were not randomized.
Use of Real World Evidence for approval of drugs to treat depression has been emphasized in a recent White

NRx Pharmaceuticals (Nasdaq:NRXP) notes presentation by Osmind, Inc. of IV Ketamine Efficacy vs. Nasal esketamine Efficacy at American Society of Clinical Psychopharmacology.

Fri, 05 Jun 2026 08:50:00 -0400

Osmind presented a retrospective comparative study of de-identified electronic health record data in a sample of 8,224 patients with treatment resistant depression treated with IV ketamine and 1,830 patients treated with intranasal esketamine from 800 community psychiatry clinics.
IV ketamine patients demonstrated significantly higher rates of remission (OR 1.51; P<.001) from depression and response (OR 1.22; P<.003) compared to patients treated with nasal esketamine.
The primary study limitation is that treatment assignments were not randomized.
Use of Real World Evidence for approval of drugs to treat depression has been emphasized in a recent White

NRx Pharmaceuticals (Nasdaq:NRXP) notes presentation by Osmind, Inc. of IV Ketamine Efficacy vs. Nasal esketamine Efficacy at American Society of Clinical Psychopharmacology.

Fri, 05 Jun 2026 08:50:00 -0400

Osmind presented a retrospective comparative study of de-identified electronic health record data in a sample of 8,224 patients with treatment resistant depression treated with IV ketamine and 1,830 patients treated with intranasal esketamine from 800 community psychiatry clinics.
IV ketamine patients demonstrated significantly higher rates of remission (OR 1.51; P<.001) from depression and response (OR 1.22; P<.003) compared to patients treated with nasal esketamine.
The primary study limitation is that treatment assignments were not randomized.
Use of Real World Evidence for approval of drugs to treat depression has been emphasized in a recent White

NRx Pharmaceuticals (Nasdaq:NRXP) notes presentation by Osmind, Inc. of IV Ketamine Efficacy vs. Nasal esketamine Efficacy at American Society of Clinical Psychopharmacology.

Fri, 05 Jun 2026 08:50:00 -0400

Osmind presented a retrospective comparative study of de-identified electronic health record data in a sample of 8,224 patients with treatment resistant depression treated with IV ketamine and 1,830 patients treated with intranasal esketamine from 800 community psychiatry clinics.
IV ketamine patients demonstrated significantly higher rates of remission (OR 1.51; P<.001) from depression and response (OR 1.22; P<.003) compared to patients treated with nasal esketamine.
The primary study limitation is that treatment assignments were not randomized.
Use of Real World Evidence for approval of drugs to treat depression has been emphasized in a recent White

NRx Pharmaceuticals (Nasdaq:NRXP) notes presentation by Osmind, Inc. of IV Ketamine Efficacy vs. Nasal esketamine Efficacy at American Society of Clinical Psychopharmacology.

Fri, 05 Jun 2026 08:50:00 -0400

Osmind presented a retrospective comparative study of de-identified electronic health record data in a sample of 8,224 patients with treatment resistant depression treated with IV ketamine and 1,830 patients treated with intranasal esketamine from 800 community psychiatry clinics.
IV ketamine patients demonstrated significantly higher rates of remission (OR 1.51; P<.001) from depression and response (OR 1.22; P<.003) compared to patients treated with nasal esketamine.
The primary study limitation is that treatment assignments were not randomized.
Use of Real World Evidence for approval of drugs to treat depression has been emphasized in a recent White

NRx Pharmaceuticals (Nasdaq:NRXP) notes presentation by Osmind, Inc. of IV Ketamine Efficacy vs. Nasal esketamine Efficacy at American Society of Clinical Psychopharmacology.

Fri, 05 Jun 2026 08:50:00 -0400

Osmind presented a retrospective comparative study of de-identified electronic health record data in a sample of 8,224 patients with treatment resistant depression treated with IV ketamine and 1,830 patients treated with intranasal esketamine from 800 community psychiatry clinics.
IV ketamine patients demonstrated significantly higher rates of remission (OR 1.51; P<.001) from depression and response (OR 1.22; P<.003) compared to patients treated with nasal esketamine.
The primary study limitation is that treatment assignments were not randomized.
Use of Real World Evidence for approval of drugs to treat depression has been emphasized in a recent White

NRx Pharmaceuticals (Nasdaq:NRXP) notes presentation by Osmind, Inc. of IV Ketamine Efficacy vs. Nasal esketamine Efficacy at American Society of Clinical Psychopharmacology.

Fri, 05 Jun 2026 08:50:00 -0400

Osmind presented a retrospective comparative study of de-identified electronic health record data in a sample of 8,224 patients with treatment resistant depression treated with IV ketamine and 1,830 patients treated with intranasal esketamine from 800 community psychiatry clinics.
IV ketamine patients demonstrated significantly higher rates of remission (OR 1.51; P<.001) from depression and response (OR 1.22; P<.003) compared to patients treated with nasal esketamine.
The primary study limitation is that treatment assignments were not randomized.
Use of Real World Evidence for approval of drugs to treat depression has been emphasized in a recent White

NRx Pharmaceuticals (Nasdaq:NRXP) notes presentation by Osmind, Inc. of IV Ketamine Efficacy vs. Nasal esketamine Efficacy at American Society of Clinical Psychopharmacology.

Fri, 05 Jun 2026 08:50:00 -0400

Osmind presented a retrospective comparative study of de-identified electronic health record data in a sample of 8,224 patients with treatment resistant depression treated with IV ketamine and 1,830 patients treated with intranasal esketamine from 800 community psychiatry clinics.
IV ketamine patients demonstrated significantly higher rates of remission (OR 1.51; P<.001) from depression and response (OR 1.22; P<.003) compared to patients treated with nasal esketamine.
The primary study limitation is that treatment assignments were not randomized.
Use of Real World Evidence for approval of drugs to treat depression has been emphasized in a recent White

Form 8-K NRX Pharmaceuticals, For: Jun 03

Thu, 04 Jun 2026 17:20:00 -0400

si-local-file:///var/storage/secattach/20260604/26606820.html

Form 8-K NRX Pharmaceuticals, For: Jun 03

Thu, 04 Jun 2026 17:20:00 -0400

si-local-file:///var/storage/secattach/20260604/26606820.html

NRX Pharmaceuticals closes $22.3 million stock offering

Thu, 04 Jun 2026 17:12:26 -0400

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) completed its public offering of common stock, raising approximately $22.3 million in gross proceeds before underwriting fees and expenses.

The clinical-stage biopharmaceutical company sold shares at $3.50 per share, with the offering including the exercise of underwriters' option to purchase additional shares. BTIG LLC served as lead bookrunning manager while Lucid Capital Markets LLC acted as joint bookrunning manager.

The company plans to use net proceeds for working capital and general corporate purposes to support growth, according to the announcement.

"We at NRx thank the fundamental healthcare investors together with BTIG and Lucid who have placed their trust

NRX Pharmaceuticals closes $22.3 million stock offering

Thu, 04 Jun 2026 17:12:26 -0400

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) completed its public offering of common stock, raising approximately $22.3 million in gross proceeds before underwriting fees and expenses.

The company plans to use net proceeds for working capital and general corporate purposes to support growth, according to the announcement.

"We at NRx thank the fundamental healthcare investors together with BTIG and Lucid who have placed their trust

NRX Pharmaceuticals closes $22.3 million stock offering

Thu, 04 Jun 2026 17:12:26 -0400

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) completed its public offering of common stock, raising approximately $22.3 million in gross proceeds before underwriting fees and expenses.

The company plans to use net proceeds for working capital and general corporate purposes to support growth, according to the announcement.

"We at NRx thank the fundamental healthcare investors together with BTIG and Lucid who have placed their trust